One of the Directors of DevelRx, David Heal, will be participating in the 86th Annual Meeting of the College on Problems of Drug Dependence to be held at Fairmont The Queen Elizabeth Hotel in Montreal, Quebec, Canada, 15th-19th June, 2024.
We have two posters describing non-clinical studies to evaluate the abuse and dependence potential of the cholesterol-24-hydroxylase inhibitor, soticlestat, that is being developed by Takeda for the treatment of seizures in Dravet syndrome and Lennox-Gastaut syndrome. These posters are with Kristin Horn, Gvido Cebers and James Blank of Takeda Development Center Americas, Inc and Sharon Rowton of Labcorp.
T169. Evaluation of the Abuse Potential of the Cholesterol-24-Hydroxylase Inhibitor, Soticlestat, in Drug-Discrimination and Self-Administration Tests. David Heal, Sharon Rowton, Sharon Smith, Jane Gosden, Kristin Horn, Gvido Cebers, James Blank. Tuesday 18th June 2024. 5:30 pm - 7 pm. Agora & Centre-Ville, Lobby Level
T171. Assessment of Withdrawal-Induced Physical Dependence in Rats after Administration of the Potent Cholesterol-24-Hydroxylase Inhibitor, Soticlestat. Sharon Rowton, David Heal, Sharon Smith, Jane Gosden, Kristin Horn, Gvido Cebers, James Blank. Tuesday 18th June 2024. 5:30 pm - 7 pm. Agora & Centre-Ville, Lobby Level
DevelRx also has a poster comparing the antinociceptive and aversive effects of the kappa opioid receptor agonists, nalfurafine and U50,488, with Eloise Kuijer, our PhD student with Chris Bailey, Sarah Bailey and Sue Wonnacott of the Department of Life Sciences, University of Bath.
W58. Nalfurafine is Aversive at Analgesic Doses – Non-Clinical Evidence to Indicate It is Not an Atypical Kappa Opioid Receptor Agonist. Eloise Kuijer, Sarah Bailey, Sue Wonnacott, Chris Bailey, David Heal, Sharon Smith. Wednesday 19th June 2024. 2.15 pm – 3.45 pm. Agora & Centre-Ville, Lobby Level
David would be pleased to see you at any of the posters. If you would like a specific meeting with him at the CPDD to discuss how DevelRx can support the development of your novel centrally-acting compounds please get in touch.